Sino-American Pharmaceutical Co., Ltd. Q4 2025 EPS NT$1.92
Sino-American Pharmaceutical Co., Ltd. (1734) reported its Q4 2025 financial results, with basic earnings per share (EPS) at NT$1.92. The company's revenue was NT$3.371 billion, and net profit after tax was NT$354 million.
📋 Article Processing Timeline
- 📰 Published: December 1, 2025 at 09:00
- 🔍 Collected: April 7, 2026 at 08:00 (3047h 0m after Published)
- 🤖 AI Analyzed: April 8, 2026 at 00:20 (16h 20m after Collected)
Sino-American Pharmaceutical Co., Ltd. (Stock Code: 1734) announced its financial results for the fourth quarter of 2025. The company, operating in the biotechnology and healthcare industry, reported basic earnings per share (EPS) of NT$1.92. Revenue for the quarter stood at NT$3.371 billion, with a net profit after tax of NT$354 million.
FAQ
What is Sino-American Pharmaceutical's stock code?
Sino-American Pharmaceutical's stock code is 1734.
What industry does Sino-American Pharmaceutical belong to?
Sino-American Pharmaceutical belongs to the biotechnology and healthcare industry.
What were Sino-American Pharmaceutical's Q4 2025 earnings per share?
Sino-American Pharmaceutical's Q4 2025 basic earnings per share (EPS) were NT$1.92.
What was Sino-American Pharmaceutical's revenue in Q4 2025?
Sino-American Pharmaceutical's revenue in Q4 2025 was NT$3.371 billion.
What was Sino-American Pharmaceutical's net profit after tax in Q4 2025?
Sino-American Pharmaceutical's net profit after tax in Q4 2025 was NT$354 million.